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ABSTRACT
Although Escherichia coli is the most common cause of bloodstream infection, its epidemiology has not
been well deﬁned in non-selected populations. We sought to describe the incidence of risk factors for,
and outcomes associated with, E. coli bacteraemia. Population-based surveillance for E. coli bacteraemia
was conducted in the Calgary Health Region (population 1.2 million) during the period 2000–2006. In
total, 2368 episodes of E. coli bacteraemia were identiﬁed for an overall annual population incidence of
30.3 ⁄ 100 000; 15% were nosocomial, 32% were healthcare-associated community-onset and 53% were
community-acquired bacteraemias. The very young and the elderly were at highest risk for E. coli
bacteraemia. Sixty per cent of the episodes occurred in females (relative risk 1.5; 95% CI 1.4–1.6).
Dialysis, solid organ transplantation and neoplastic disease were the most important risk factors for
acquiring E. coli bacteraemia. Rates of resistance to ampicillin, trimethoprim–sulphamethoxazole,
gentamicin, ciproﬂoxacin, cefazolin and ceftriaxone increased signiﬁcantly during the period 2000–2006.
The case-fatality rate was 11% and the annual population mortality rate was 2.9 ⁄ 100 000. Increasing age,
ciproﬂoxacin resistance, non-urinary focus and a number of comorbid illnesses were independently
associated with an increased risk of death, and community acquisition and urinary focus were
associated with a lower risk of death. This study documents the major burden of illness associated with
E. coli bacteraemia and identiﬁes groups at increased risk for acquiring and dying from these infections.
The emergence of ciproﬂoxacin resistance and its adverse effect on patient outcome is a major concern.
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INTRODUCTION
Escherichia coli ranks ﬁrst and second as the most
common cause of community-acquired and hos-
pital-acquired bloodstream infection, respectively
[1–7]. E. coli bloodstream infections usually arise
as a complication of focal infections of the urinary
or gastrointestinal tracts, although occasionally
they also cause primary bacteraemia without a
deﬁned source. E. coli is also a major cause of
invasive infections, including bacteraemic sepsis
and meningitis in the neonatal period [1,8]. Rates
of antimicrobial resistance in E. coli have
increased in recent years. Resistance to a number
of classes of antimicrobials has been observed,
and the emergence of strains with AmpC-type
b-lactamases and extended-spectrum b-lacta-
mases (ESBLs) [9–13] is of most concern. Several
studies have reported on the clinical features and
outcomes of E. coli bacteraemia within selected
populations [7,14–23]. Case-fatality rates in these
predominantly hospital-based studies have ran-
ged broadly from 5% to 30%, probably reﬂecting,
at least in part, the selected case mix of cohorts
studied and the impact of resistant organisms.
Despite the paramount importance of E. coli
bloodstream infections, their epidemiology has
rarely been evaluated in a non-selected popula-
tion [24]. Although population-based studies
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investigating the epidemiology of bloodstream
infections in general have been conducted, spe-
ciﬁc risk factors and outcomes associated with
E. coli bacteraemia are not well deﬁned or
described [2–6,24]. The objective of this study
was to conduct population-based surveillance in a
large Canadian region during the period 2000–
2006 in order to deﬁne the incidence, risk factors
for acquisition and outcomes of E. coli blood-
stream infections.
METHODS
Study population
TheCalgaryHealthRegion (CHR) provides virtually allmedical
and surgical care to the residents of the cities of Calgary and
Airdrie and a large surrounding area (population 1.2 million) in
the Province of Alberta, Canada. Only patients requiring acute
liver, heart or lung transplantation surgeryare routinely referred
elsewhere for care.All personswho resided in theCHRandwho
developed bacteraemic E. coli infection during the period 1
January 2000 to 31 December 2006 were included in the study.
The Conjoint Health Research Ethics Board at the University of
Calgary and the CHR approved this study and waived the
requirement for individual written informed consent.
Study protocol
An active, population-based surveillance cohort design was
utilized. Surveillance for bacteraemic E. coli infections was
conducted by Calgary Laboratory Services, a regional labora-
tory system that receives more than 95% of all blood samples
submitted for culture from hospitals, nursing homes and
clinics in the CHR. Further clinical and outcome details were
obtained concerning all patients admitted to any of the four
major acute-care hospitals (representing ‡95% of the CHR
admissions), using data available from the regional corporate
data warehouse.
Deﬁnitions
Bacteraemic E. coli infection was deﬁned on the basis of the
isolationofE. coli fromoneormore sets of aseptically inoculated
blood culture bottles. Clinical isolates were cultured, conﬁrmed
as E. coli, and tested for antimicrobial susceptibility by standard
techniques. At Calgary Laboratory Services, all E. coli isolates
are routinely screened for ESBL and AmpC production, as
previously described [9,10]. The presence or absence of E. coli
cultures obtained from non-blood sites within c. 48 h of the
index incident blood culture draw was also assessed. Incident
cases were deﬁned as those of the initial isolation of E. coli from
blood of a CHR resident; repeated isolation within 365 days
after the ﬁrst isolation was deemed to represent the same
incident infection. Residency status was established using
the 2003 boundaries of the CHR (http://www.calgaryhealth
region.ca/newslink/publications/regionhealth/pdf/health_
region_report_06.pdf). Neonatal infections were deﬁned as
those yielding a positive culture in children aged less than
90 days, and they were considered to be of early onset in
children less than 7 days old.
Nosocomial bacteraemias were deﬁned as those with ﬁrst
culture-positivity ‡48 h following hospital admission or within
48 h of discharge. Community-onset infections were deﬁned as
those with ﬁrst culture-positivity within <48 h of admission or
>48 h after discharge from hospital. A healthcare-associated
community-onset E. coli bacteraemia was in addition associ-
ated with at least one of the following: (i) discharge from an
adult home parenteral therapy clinic within 2–30 days before
bloodstream infection [25]; (ii) attendance at a hospital clinic or
emergency room within 2–30 days before bloodstream infec-
tion; (iii) admission to a CHR acute-care hospital for two or
more days within the 90 days before bloodstream infection;
(iv) sample submission from a patient who previously sent a
sample from a nursing home or a long-term-care facility; and
(v) outpatient haemodialysis.
Data on adult home parenteral therapy clinic assessment
and dialysis were not available for children, and in these cases
they were assumed to be non-existent. Community-acquired
infections were deﬁned as community-onset bacteraemias that
were not healthcare-associated.
Statistical analysis
Analysis was performed using Stata Software version 9.0
(Stata Corp., College Station, TX, USA). Non-normally distrib-
uted variables were reported as medians with interquartile
ranges (IQRs), and compared using the rank sum test for pairs
or median test for multiple groups. Differences in proportions
among categorical data were assessed using Fisher’s exact test
for pairwise comparisons and the chi-squared test for multiple
groups. The incidence of bacteraemic E. coli infections was
calculated by dividing the number of incident cases by the
total regional population. The neonatal infection rate was also
expressed as a rate per 1000 live births (106 752). Population-
based risk factors for developing E. coli bacteraemia were
quantiﬁed by dividing the incidence of these infections among
those with a given factor by those without the factor. Regional
demographic data were used to determine the population at
risk according to age and gender. For other potential risk
factors, the population at risk was ascertained or estimated
using local patient registry data [26], regional or Canadian
survey data (http://www.statcan.ca/english/freepub/82-570-
XIE/intro.htm), or published North American epidemiological
data [27–29]. Risks were expressed as incidence rate ratios
(RRs) and reported with 95% CIs. A logistic regression model
was developed to assess independent factors associated
with in-hospital deaths. Factors found to be signiﬁcant to
the p <0.1 level were included in the initial model, and
backward stepwise variable elimination was then performed
to develop the ﬁnal model. Model calibration was assessed
using the Hosmer–Lemeshow goodness-of-ﬁt test, and
discrimination was assessed using the area under the receiver
operator characteristic curve. For all statistical comparisons,
a p-value <0.05 was deemed to represent statistical
signiﬁcance.
RESULTS
During the 7-year study, 2368 incident bacterae-
mic E. coli infections occurred among 2316 CHR
residents; 47 patients had two incident episodes,
and ﬁve patients had three incident episodes.
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Basic demographic (age, gender, residency) and
microbiological data were available for all
patients, and further clinical and outcome infor-
mation was available for the 2041 ⁄ 2368 (86%)
incident cases managed at one of the four major
acute-care centres in the CHR. Among the 2368
incident bacteraemic E. coli infections, 364 (15%)
were classiﬁed as nosocomial, 758 (32%) as
healthcare-associated community-onset, and
1246 (53%) as community-acquired. The overall
annual population incidence of bacteraemic infec-
tion among residents of the CHR was
30.3 ⁄ 100 000. A relatively stable incidence was
observed during the 7 years of the study, as
shown in Fig. 1.
The median age of the patients was 67.3 years
(IQR, 49.9–79.0 years); it was signiﬁcantly
(p <0.001) lower in patients with community-
acquired infections (65.0 years; IQR, 46.9–
76.6 years) than in patients with nosocomial
(69.6 years; IQR, 51.5–80.3 years) and healthcare-
associated (71.5 years; IQR, 53.5–81.6 years)
infections. The risk of development of E. coli
bacteraemia was closely related to age, with the
very young and the elderly being at highest risk,
as shown in Fig. 2. Sixty-seven neonates
(<90 days) developed E. coli bacteraemia at a rate
of 0.63 ⁄ 1000 live births. Rates of early-onset and
late-onset disease (19 and 48 cases) were 0.18 and
0.45 ⁄ 1000 live births, respectively. Sixty per cent
(1415) of incident episodes overall occurred in
females (RR 1.5; 95% CI 1.4–1.6; p <0.0001).
However, the excess risk in females was only
observed in the age range 1–59 years (Fig. 2; RR
2.3; 95% CI 2.0–2.7), with there being no signif-
icant excess risk in the group of less than 1-year-
old or over 60-year-old patients (RR 1.0; 95% CI
0.9–1.1). However, among 48 late-onset neonatal
cases, 37 (77%) occurred in males (RR 3.2;
95% CI 1.6–7.0).
A number of selected conditions were assessed
as risk factors for acquiring E. coli bacteraemia,
and these are shown in Table 1. Solid organ
transplantation, renal dialysis and neoplastic dis-
ease were the most important risk factors. Among
transplant patients, 27 were kidney recipients,
two were lung recipients, and one each received a
kidney ⁄pancreas, liver or heart transplant.
Among the 422 patients with neoplastic disease,
270 (64%) had malignant tumours, 96 (23%) had
haematological malignancies, one patient had
both a tumour and a haematological malignancy,
and 55 (13%) patients had neoplastic disease in
0
5
10
15
20
25
30
35
40
2000
Year
In
ci
de
nc
e 
(p
er
 10
0 0
00
/ye
ar
)
CA HCA NA
2001 2002 2003 2004 2005 2006
Fig. 1. Annual incidence of Escherichia coli bloodstream
infections in the Calgary Health Region, Canada, 2000–
2006. CA, community-acquired; HCA, healthcare-associ-
ated community-onset; NA, nosocomial-acquired.
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Fig. 2. Age-speciﬁc incidence of Escherichia coli blood-
stream infections in the Calgary Health Region, Canada,
2000–2006.
Table 1. Risk of Escherichia coli bacteraemia associated
with selected underlying conditions
Factor Age groupa Number (%) RR (95% CI) p-value
Dialysis 20+ 28 (1) 29.6 (19.6–43.0) <0.0001
Organ transplant All 33 (2) 20.3 (13.9–28.6) <0.0001
Cancer 20+ 422 (22) 14.9 (13.4–16.7) <0.0001
Diabetes 12+ 370 (19) 7.2 (6.4–8.0) <0.0001
Heart disease 12+ 399 (21) 6.2 (5.6–7.0) <0.0001
HIV infection All 6 (<1) 4.2 (1.5–9.2) 0.0042
Stroke 12+ 63 (3) 3.3 (2.5–4.3) <0.0001
COPD 12+ 159 (8) 2.9 (2.4–3.4) <0.0001
Crohn’s disease All 11 (1) 1.9 (1.0–3.4) 0.049
Rheumatoid arthritis 20+ 36 (2) 1.9 (1.3–2.6) 0.0005
Ulcerative colitis All 7 (<1) 1.9 (0.7–3.8) 0.13
Alcoholism 20+ 129 (7) 1.7 (1.4–2.1) <0.0001
Systemic lupus
erythematosus
20+ 12 (1) 1.7 (0.9–3.0) 0.089
Hepatitis C All 26 (1) 1.4 (0.9–2.1) 0.087
Asthma 12+ 47 (2) 0.3 (0.2–0.4) <0.0001
RR, rate ratio; COPD, chronic obstructive pulmonary disease.
aNumber of cases in age groups: all ages, n = 2041; 12 + (12 years and older),
n = 1935; 20 + (20 years and older), n = 1916.
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remission. Among the 270 malignant tumours,
gastrointestinal tract (115; 43%), genitourinary
tract (53; 20%) and lung (31; 11%) cancers were
most frequently observed, and 145 (54%) were
metastatic.
Among the incident 2368 cases, cultures of
E. coli were positive from a non-blood site within
48 h of the index blood culture draw in 1121
(47%) cases. These cultures were obtained from
urine in 1070 (45%) cases, intra-abdominal sam-
ples in 25 (1%), lower respiratory tract samples in
21 (1%), soft tissue in ﬁve (<1%), bone ⁄ joint
samples in three, and central nervous system
samples in two; one sample each was from the
upper respiratory tract and the genitourinary
tract.
Antimicrobial susceptibility testing results were
available for 2355 (99%) of incident blood isolates.
Reduced susceptibility (intermediate susceptibil-
ity or resistance) to ampicillin occurred in 986
(42%) cases, to trimethoprim–sulphamethoxazole
in 508 (22%), to gentamicin in 212 (9%), and to
cefazolin in 172 (7%). Among isolates tested,
reduced susceptibility to amoxycillin–clavulanate
was observed in 428 ⁄ 2226 (19%) cases, to cipro-
ﬂoxacin in 257 ⁄ 2204 (12%), to ceftriaxone in
81 ⁄ 2192 (4%), to piperacillin–tazobactam in
60 ⁄ 2197 (3%), and to imipenem in 0 ⁄ 1482. AmpC-
and ESBL-producing isolates were identiﬁed in 32
(1%) and 50 (2%) cases, respectively, predomi-
nantly of community-onset infections (25 ⁄ 32; 78%
and 41 ⁄ 50; 82%). During the 7 years of the study,
rates of resistance to all of the antimicrobials tested,
except imipenem, trimethoprim–sulphameth-
oxazole and piperacillin–tazobactam, increased
signiﬁcantly (p <0.05), as shown in Fig. 3.
The overall median length of hospital stay was
8.3 days (IQR, 4.8–16.5 days) and was signiﬁ-
cantly (p <0.0001) longer for patients with noso-
comial (25.8 days; IQR, 14.3–50.4 days) infections
than for those with healthcare-associated
(7.8 days; IQR, 4.7–13.4 days) and community-
acquired (6.6 days; IQR, 4.1–11.0 days) infections.
The median time from admission to development
of nosocomial bacteraemia was 9.3 days (IQR,
4.2–18.9 days). The case-fatality rate was 230 ⁄ 2041
(11%) for an annual population mortality rate of
2.9 ⁄ 100 000. A multivariable logistic regression
model was developed (n = 1896) to assess factors
associated with death, and had both good
discrimination (area under receiver operator
characteristic = 0.794) and calibration (Hosmer–
Lemeshow goodness-of-ﬁt test p 0.66). Increasing
age, ciproﬂoxacin resistance, nosocomial acquisi-
tion, non-urinary focus and a number of comor-
bid illnesses were independently associated with
an increased risk of death, as shown in Table 2.
DISCUSSION
In this article, novel population-based data
describing the incidence, risk factors for and
outcome of E. coli bacteraemia in a large Cana-
dian population (c. 8 million person-years of
observation) are reported, and a contribution is
made to the body of literature concerning factors
associated with death due to these infections.
Population-based studies minimize selection
bias, enable incidence rate calculations, and facil-
itate standardized comparisons among different
regions and time periods. Few contemporary
studies are available for comparison of the inci-
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Fig. 3. Rates of antimicrobial resistance among Escherichia
coli isolates from bloodstream infections in the Calgary
Health Region, Canada, 2000–2006. TMP ⁄ SMX, trimetho-
prim–sulphamethoxazole.
Table 2. Logistic regression modelling of risk factors for
death in patients with Escherichia coli bacteraemia.
Factor OR (95% CI) p-value
Age 0–39 years 1.0 (reference)
Age 40–64 years 2.9 (1.3–6.7) 0.011
Age 65+ years 5.0 (2.3–11.3 <0.001
Cancer 2.4 (1.6–3.6) <0.001
Haematological malignancy 2.4 (1.3–4.5) 0.005
Community-acquired 1.0 (reference)
Healthcare-asssociated 1.7 (1.1–2.4) 0.010
Nosocomial 2.7 (1.8–4.0) <0.001
No focus 1.0 (reference)
Urinary tract focus 0.4 (0.3–0.6) <0.001
Focus other than urinary tract 5.6 (2.9–11.1) <0.001
Stroke 2.1 (1.1–4.4) 0.035
Chronic lung disease 1.6 (1.0–2.7) 0.048
Alcoholism 7.3 (4.4–12.2) <0.001
Heart disease 1.6 (1.1–2.3) 0.014
Ciproﬂoxacin resistance 1.8 (1.2–2.8) 0.008
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dence rate of 30 ⁄ 100 000 ⁄ year as reported here.
Uslan et al. [2] reported a population-based anal-
ysis of bloodstream infections occurring in Olm-
stead County, USA, during the period 2003–2005.
They found that E. coli was the most frequent
isolate (163 ⁄ 650), with an approximate unadjusted
rate of 40.5 ⁄ 100 000 ⁄year (calculated from data in
their report) [2]. Skogberg et al. [4] observed a rate
of approximately 30 ⁄ 100 000 for E. coli bacterae-
mias in Finland during the period 1995–2002.
Madsen et al. [6] reported a rate of 32 ⁄ 100 000 in
North Jutland County in Denmark during the
period 1981–1994. Most recently, Kennedy et al.
[24] reported a rate of 28 ⁄ 100 000 for E. coli bacte-
raemias in Canberra, Australia during the period
2000–2004. Putting this in context with other
aetiologies, the incidence rate for E. coli blood-
stream infections is 1.5-fold higher than that for
either Staphylococcus aureus or Streptococcus pneu-
moniae, and ten-fold higher than that for group A
and B streptococcal bacteraemias [2,4,30–37].
There are no other studies for direct compari-
son with the mortality rate of 2.9 ⁄ 100 000 repor-
ted here, because previous population-based
investigations have either reported only aggregate
data for all bloodstream infections [2,4,6] or have
follow-ups limited to only 7 days [24]. Kennedy
et al. [24] found a 5% 7-day case-fatality rate in
their population-based study from Australia.
Hospital-based studies have reported variable
case-fatality rates, broadly ranging from 5% to
29%. Melzer and Petersen [18] studied 354 adults
with E. coli bacteraemia at a hospital in Essex, UK,
and found a case-fatality rate of 29%. A 21% case-
fatality rate for E. coli bacteraemia was observed
by both Gransden et al. among 861 patients in
London, UK, and Olesen et al. in 433 episodes in a
Danish university hospital [17,20]. Vazquez et al.
[21] reported a slightly lower case-fatality rate of
18% among 474 cases in Oviedo, Spain. In
contrast, Kuikka et al. found a case-fatality rate
of 9% at a Finnish university hospital, and Peralta
et al. a rate of 5% at an adult acute-care commu-
nity teaching hospital in Torrelavega, Spain
[15,22]. The wide variability in case-fatality rates
observed in these studies probably reﬂects, at
least in part, differences in case mix among
investigations, as well as the effect of selection
bias in studies from major referral centres [38–40]
Population-based studies, by including all cases
occurring in residents of a deﬁned geographical
region, minimize this important bias.
Previous population-based studies have docu-
mented the excess risk of all bloodstream infec-
tions in association with advancing age [2,4].
Uslan et al. identiﬁed an increased risk of E. coli
bacteraemia in females across all age ranges
which contrasts with the current observation of
an excess risk in only 1–59-year-old females
(Fig. 2). In contrast, Kennedy et al. [24] found that
elderly males were at highest risk. Several hospi-
tal-based studies have suggested that a number of
comorbid illnesses, including diabetes, malig-
nancy, chronic lung disease, cirrhosis and heart
disease, may increase the risk of E. coli bactera-
emia [15,18,20]. However, to our knowledge, the
present study is the ﬁrst designed to quantify
actual risk factors for the development of E. coli
bacteraemia in a general, non-selected population
(Table 1). There are several potential risk factors
for E. coli bacteraemia that were not assessed in
this study, e.g. chronic urinary catheterization,
urinary incontinence and other urinary tract
abnormalities, and this is a limitation of the
study. Jackson et al. [19] conducted a case–control
study nested within a large-cohort study of
community-onset E. coli bacteraemias in seniors.
They found that urinary catheterization and
incontinence were risk factors in males, and that
cancer, renal failure, heart disease and urinary
incontinence were risk factors in females [19].
The rate of resistance to antimicrobials and its
effect on rates of mortality merits discussion. As
compared to most other large contemporary
series of E. coli bacteraemia [14,15,18,24], overall
lower rates of resistance to most antimicrobials
tested were observed in this study; however, they
are increasing (Fig. 3).
Previous studies have identiﬁed advancing
age, hospital acquisition, comorbid illnesses,
presence of shock, non-urinary focus and anti-
microbial resistance in conjunction with inade-
quate treatment as being associated with death
[15,17,18,20,41]. Melzer and Petersen [18] found
that the adjusted OR for death associated with
ESBL-producing isolates was 3.6 (95% CI 1.5–
8.6). Peralta et al. [15] found that resistance to
each antibiotic, except gentamicin, was associ-
ated with increased crude risk of death,
and that multidrug-resistant (ESBL- or AmpC-
producing, or resistant to three or more stan-
dard antimicrobials) E. coli accounted for an
adjusted 3.1-fold (95% CI 1.3–7.4) increased
risk of death.
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These authors identiﬁed the effect of antimicro-
bial resistance as being an increased risk of receiv-
ing inadequate therapy. These ﬁndings contrast
with those of the present study, in which only
ciproﬂoxacin resistance was associated with a
crude and adjusted risk of death (Table 2). It is
notable that neither the presence of AmpC or ESBL
enzymes, nor multidrug resistance or resistance to
antimicrobials other than ciproﬂoxacin, was asso-
ciated with adverse outcome in this study. Unfor-
tunately, antimicrobial utilization data were not
available for this study, and therefore it was not
possible to assess the potential effect of adequacy of
therapy on outcome.
Although a rigorous population-based design
was utilized, there are some study limitations that
merit discussion. Only patients who had a
positive blood culture for E. coli were included
in this study. Patients who may have had E. coli
bacteraemia but from whom no sample was
submitted for culture would not have been
identiﬁed in this study. The rates presented
should therefore be viewed as conservative esti-
mates of all true E. coli bloodstream infections in
the population studied. Another limitation is that
each patient was not clinically assessed to deter-
mine a potential focus of infection; this was based,
crudely, on the presence of E. coli at other sites.
Finally, the assessment of factors associated with
rates of mortality did not include a number of
potentially important variables not limited to
adequacy and timing of antimicrobial therapy
and markers of severity of illness [15,41,42].
Although the present model had good discrimi-
nation, inclusion of these variables would prob-
ably improve the model further.
In summary, this novel study documents the
major burden of illness associated with E. coli
bacteraemia and identiﬁes groups at increased
risk for acquiring and dying from these infec-
tions. Ongoing surveillance for E. coli bactera-
emia will be important to track the burden of
disease and the adverse impact of antimicrobial
resistance.
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